Corcept Therapeutics, Inc. (CORT)
116.18
-2.32
(-1.96%)
USD |
NASDAQ |
Sep 25, 16:00
116.18
0.00 (0.00%)
After-Hours: 19:28
Corcept Therapeutics Research and Development Expense (Annual) : 254.91M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 254.91M |
| December 31, 2024 | 246.89M |
| December 31, 2023 | 184.35M |
| December 31, 2022 | 130.99M |
| December 31, 2021 | 113.86M |
| December 31, 2020 | 114.76M |
| December 31, 2019 | 89.02M |
| December 31, 2018 | 75.25M |
| December 31, 2017 | 40.38M |
| December 31, 2016 | 23.84M |
| December 31, 2015 | 15.42M |
| December 31, 2014 | 18.37M |
| Date | Value |
|---|---|
| December 31, 2013 | 20.47M |
| December 31, 2012 | 14.07M |
| December 31, 2011 | 21.00M |
| December 31, 2010 | 18.95M |
| December 31, 2009 | 14.40M |
| December 31, 2008 | 14.15M |
| December 31, 2007 | 7.86M |
| December 31, 2006 | 20.83M |
| December 31, 2005 | 17.07M |
| December 31, 2004 | 11.55M |
| December 31, 2003 | 8.108M |
| December 31, 2002 | 13.15M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Illumina, Inc. | 951.00M |
| Eli Lilly & Co. | 13.34B |
| Pfizer Inc. | 10.25B |
| Merck & Co., Inc. | 12.51B |
| Aclaris Therapeutics, Inc. | 52.64M |